Temporary suspension for closed-loop medicament therapy

US9669160B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9669160-B2
Application numberUS-201514813699-A
CountryUS
Kind codeB2
Filing dateJul 30, 2015
Priority dateJul 30, 2014
Publication dateJun 6, 2017
Grant dateJun 6, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A portable infusion pump can communicate with continuous glucose monitor (CGM) to receive continuous feedback relating to a user's blood glucose level during insulin or other medicament therapy and can automatically deliver insulin to a user when the CGM data indicates a need for additional insulin. Because patient behavior can interfere with the accuracy and efficacy of such closed loop or semi-closed loop therapy, a system can employ various mechanisms for manual temporary suspension of closed-loop therapy when a patient is aware that current or future behavior may inhibit therapy.

First claim

Opening claim text (preview).

The invention claimed is: 1. An infusion pump system, comprising: a delivery mechanism adapted to facilitate delivery of medicament to a patient; memory adapted to store parameters relating to the delivery of medicament; a communications device adapted to receive information from a continuous glucose monitor; and a processor functionally linked to the delivery mechanism and the memory and to the communications device to obtain the information from the continuous glucose monitor, the processor configured to: cause the delivery mechanism to deliver medicament to the patient according to therapy parameters determined based on the information from the continuous glucose monitor; determine from user-defined input that the patient is going to take or has taken a medication; suspend delivery of medicament according to the determined therapy parameters for a suspension period in response to the determination that the patient is going to take or has taken a medication; cause the delivery mechanism to deliver medicament according to a default medicament delivery schedule stored in memory during the suspension period; and resume causing the delivery mechanism to deliver medicament to the patient according to the determined therapy parameters following the suspension period, and wherein the processor is further configured to receive a duration for the suspension period entered through a user interface in communication with the processor. 2. The portable infusion pump of claim 1 , wherein the processor is further configured to receive an indication of a type of medication the patient is going to take or has taken. 3. The portable infusion pump of claim 2 , wherein the processor is further configured to determine whether the type of medication is one likely to cause the information from the continuous glucose monitor to become unreliable, and suspend delivery of the medicament only if the type of medication is one likely to cause the information from the continuous glucose monitor to become unreliable. 4. The portable infusion pump of claim 1 , wherein the processor is configured to resume causing the delivery mechanism to deliver medicament to the patient according to the determined therapy parameters automatically following the suspension period. 5. The portable infusion pump of claim 1 , wherein the processor is further configured to provide a prompt on the user interface in communication with the processor that the suspension period has ended and to resume causing the delivery mechanism to deliver the medicament to the patient according to the determined therapy parameters following the suspension period only after receiving a confirmation in response to the prompt. 6. The portable infusion pump of claim 1 , wherein the processor is configured to determine the therapy parameters based on the information from the continuous glucose monitor. 7. An infusion pump system, comprising: a delivery mechanism adapted to facilitate a delivery of a medicament to a patient; a memory adapted to store parameters relating to the delivery of the medicament; a communications device adapted to receive information from a continuous glucose monitor; and a processor functionally linked to the delivery mechanism and the memory and to the communications device to obtain the information from the continuous glucose monitor, the processor configured to: cause the delivery mechanism to deliver the medicament to the patient according to therapy parameters determined based on the information from the continuous glucose monitor; determine from user-defined input that the patient is going to take or has taken a medication; suspend delivery of the medicament according to the determined therapy parameters for a suspension period in response to the determination that the patient is going to take or has taken a medication; cause the delivery mechanism to deliver the medicament according to a default medicament delivery schedule stored in the memory during the suspension period; and resume causing the delivery mechanism to deliver the medicament to the patient according to the determined therapy parameters following the suspension period, and wherein the processor is further configured to receive an indication of the type of the medication the patient is going to take or has taken and determine a duration for the suspension period based on the type of the medication. 8. The portable infusion pump of claim 7 , wherein the processor additionally determines the duration for the suspension period based at least in part on a dosage size of the medication. 9. The portable infusion pump of claim 7 , wherein the processor is further configured to determine whether the type of the medication is on likely to cause the information from the continuous glucose monitor to become unreliable, and suspend delivery of the medicament only if the type of the medication is one likely to cause the information from the continuous glucose monitor to become unreliable. 10. The portable infusion pump of claim 7 , wherein the processor is configured to resume causing the delivery mechanism to deliver the medicament to the patient according to the determined therapy parameters automatically following the suspension period. 11. The portable infusion pump of claim 7 , wherein the processor is further configured to provide a prompt a user interface in communication with the processor that suspension period has ended and to resume causing the delivery mechanism to deliver the medicament to the patient according to the determined therapy parameters following the suspension period only after receiving a confirmation in response to the prompt. 12. The portable infusion pump of claim 7 , wherein the processor is configured to determine the therapy parameters based on the information from the continuous glucose monitor. 13. An infusion pump system, comprising: a delivery mechanism adapted to facilitate a delivery of a medicament to a patient; a memory adapted to store parameters relating to the delivery of the medicament; a communications device adapted to receive information from a continuous glucose monitor; and a processor functionally linked to the delivery mechanism and the memory and to the communications device to obtain the information from the continuous glucose monitor, the processor configured to: cause the delivery mechanism to deliver the medicament to the patient according to therapy parameters determined based on the information from the continuous glucose monitor; receive an indication that the patient is going to take or has taken a medication; suspend delivery of the medicament according to the determined therapy parameters for a suspension period in response to the indication; cause the delivery mechanism to deliver the medicament according to a default medicament delivery schedule stored in the memory during the suspension period; and resume causing the delivery mechanism to deliver the medicament to the patient according to the determine therapy parameters following the suspension period, wherein the processor is further configured to receive an indication of a type of medication the patient is going to take or has taken, and wherein the processor is further configured to determine whether the type of medication is one likely to cause the information from the continuous glucose monitor to become unreliable, and suspend delivery of the medicament only if the type of medication is one likely to cause the information from the continuous glucose monitor to become unreliable. 14. The portable infusion pump of claim 13 , wherein the processor is further configured to re

Assignees

Inventors

Classifications

  • with a programmable infusion control system, characterised by the infusion program · CPC title

  • for computer-aided diagnosis, e.g. based on medical expert systems · CPC title

  • A61M5/1723Primary

    using feedback of body parameters, e.g. blood-sugar, pressure (measurement of body parameters A61B5/00) · CPC title

  • adapted to be carried by the patient, e.g. portable on the body · CPC title

  • Glucose concentration · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9669160B2 cover?
A portable infusion pump can communicate with continuous glucose monitor (CGM) to receive continuous feedback relating to a user's blood glucose level during insulin or other medicament therapy and can automatically deliver insulin to a user when the CGM data indicates a need for additional insulin. Because patient behavior can interfere with the accuracy and efficacy of such closed loop or sem…
Who is the assignee on this patent?
Tandem Diabetes Care Inc
What technology area does this patent fall under?
Primary CPC classification A61M5/1723. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).